These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34844257)

  • 21. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
    Freedman SF; Hercinovic A; Wallace DK; Kraker RT; Li Z; Bhatt AR; Boente CS; Crouch ER; Hubbard GB; Rogers DL; VanderVeen D; Yang MB; Cheung NL; Cotter SA; Holmes JM;
    Ophthalmology; 2022 Oct; 129(10):1120-1128. PubMed ID: 35660415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extending Peripheral Retinal Vascularization in Retinopathy of Prematurity Through Regulation of VEGF Signaling.
    Sauer L; Chandler M; Hartnett ME
    Am J Ophthalmol; 2024 Apr; 260():190-199. PubMed ID: 38141904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aggressive Posterior Retinopathy of Prematurity Treated with Intravitreal Bevacizumab: Late Period Fluorescein Angiographic Findings.
    Perente I; Eris E; Seymen Z; Cevik SG; Bekmez S
    Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1141-1146. PubMed ID: 30895452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab monotherapy for retinopathy of prematurity.
    Şahin A; Şahin M; Cingü AK; Çınar Y; Türkcü FM; Yüksel H; Kaya S; Arı Ş; Caça İ
    Pediatr Int; 2013 Oct; 55(5):599-603. PubMed ID: 23659781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.
    Padhi TR; Das T; Rath S; Pradhan L; Sutar S; Panda KG; Modi R; Jalali S
    Eye (Lond); 2016 Mar; 30(3):392-9. PubMed ID: 26584796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review.
    Frosini S; Franco F; Vicini G; Nicolosi C; Varriale G; Dani C; Virgili G; Giansanti F
    J Matern Fetal Neonatal Med; 2022 Sep; 35(17):3337-3342. PubMed ID: 32933350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab.
    Alyamaç Sukgen E; Çömez A; Koçluk Y; Cevher S
    Ophthalmologica; 2016; 236(3):139-147. PubMed ID: 27682852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
    Sindal MD; Nagesha CK; Yadav D; Fazal R
    Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina.
    Gonzalez A; Agarwal-Sinha S
    Can J Ophthalmol; 2020 Oct; 55(5):373-381. PubMed ID: 32835673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
    Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
    Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal injection of bevacizumab for retinopathy of prematurity.
    Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
    Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
    Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
    J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP.
    Ekinci DY; Vural AD; Bayramoglu SE; Onur IU; Hergunsel GO
    Int Ophthalmol; 2019 Dec; 39(12):2697-2705. PubMed ID: 30830544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiographic Review of Choroidal Involution in Eyes with Retinopathy of Prematurity Treated with Bevacizumab.
    Islam Y; Andersen L; Agarwal-Sinha S
    Ophthalmic Res; 2022; 65(2):229-236. PubMed ID: 33113546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
    ; Hartnett ME; Wallace DK; Dean TW; Li Z; Boente CS; Dosunmu EO; Freedman SF; Golden RP; Kong L; Prakalapakorn SG; Repka MX; Smith LE; Wang H; Kraker RT; Cotter SA; Holmes JM
    JAMA Ophthalmol; 2022 Apr; 140(4):337-344. PubMed ID: 35446359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.